2017 Press Releases


Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
December 4, 2017
Positive Preclinical Data from Xenon’s XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual Meeting
Data Suggest Xenon’s Selective Nav1.6 Sodium Channel Inhibitor, XEN901, Provides Efficacy with a Potentially Improved Safety Profile over Other Non-Selective, Sodium Channel Blocker Anti-Epileptic Drugs (AEDs) BURNABY, British Columbia, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.... More >>
November 8, 2017
Xenon Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
BURNABY, British Columbia, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Stifel 2017 Healthcare C... More >>
November 7, 2017
Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
BURNABY, British Columbia, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended September 30, 2017, and provided a corporate update. Dr. Simon Pimstone, Xenon's Presiden... More >>
November 1, 2017
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 third quarter financial and operating results after the close of U.S. financial markets on Tuesday, Novemb... More >>
October 17, 2017
Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial
Xenon’s innovative, proprietary epilepsy programs continue to advance in development Pharmacodynamic read-out expected in Q1 2018 and XEN1101 Phase 2 proof-of-concept clinical trial anticipated to begin in Q3 2018 BURNABY, British Columbia, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceut... More >>
August 3, 2017
Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
BURNABY, British Columbia, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended June 30, 2017, and provided a corporate update for 2017. Dr. Simon Pimstone, Xenon's Pres... More >>
July 27, 2017
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update
BURNABY, British Columbia, July 27, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 second quarter financial and operating results after the close of U.S. financial markets on Thursday, Augu... More >>
June 27, 2017
Xenon Pharmaceuticals to Host Conference Call and Webcast Today at 9:00 a.m. Eastern Time to Discuss Topline Results from TV-45070 Phase 2b Clinical Trial in PHN
BURNABY, British Columbia, June 27, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced that it will host a conference call and live audio webcast at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) today to discuss the topline re... More >>
June 27, 2017
Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint
JERUSALEM and BURNABY, British Columbia , June 27, 2017 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announce top-line results in a Phase II study of topical TV-45070 in patients with post-herpetic neuralgia (PHN). TV-... More >>
June 2, 2017
Xenon Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference
BURNABY, British Columbia, June 02, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Jefferies 2017 Healthcar... More >>
May 9, 2017
Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
BURNABY, British Columbia, May 09, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company today, reported its financial results for the quarter ended March 31, 2017, and provided a corporate update for 2017. Dr. Simon Pimstone, Xenon's Pres... More >>
May 4, 2017
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results and Provide Corporate Update
BURNABY, British Columbia, May 04, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 first quarter financial and operating results after the close of U.S. financial markets on Tuesday, May 9, ... More >>
April 28, 2017
Xenon Pharmaceuticals to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference
BURNABY, British Columbia, April 28, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Bloom Burton & Co. ... More >>
April 26, 2017
Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
Phase 1 expected to begin in Q4 2017, with pharmacodynamic read-out in Q1 2018 and Phase 2 proof-of-concept clinical trial beginning in mid-2018 Conference call to be held today at 9:00 am ET BURNABY, British Columbia, April 26, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), ... More >>
March 24, 2017
Xenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints in Phase 2 Clinical Trial in Patients with Moderate to Severe Acne
Company to Hold Conference Call at 8:30 am ET Today BURNABY, British Columbia, March 24, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported topline efficacy results from the double-blind, multi-center, vehicle-controlled, ... More >>
March 8, 2017
Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update
BURNABY, British Columbia, March 08, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the year ended December 31, 2016, and provided a corporate update for 2017. Dr. Simon Pimstone, Xenon's Pr... More >>
March 1, 2017
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2016 Financial Results and Provide Corporate Update
BURNABY, British Columbia, March 01, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2016 financial and operating results after the close of U.S. financial markets on Wednesday, March 8, 2017. Xe... More >>
January 8, 2017
Xenon Pharmaceuticals Outlines Key Milestones for 2017
BURNABY, British Columbia, Jan. 08, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today outlined its anticipated key corporate milestones for 2017. Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, “As we en... More >>